about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Astel­las writes down an­oth­er piece of its Au­dentes gene ther­a­py ac­qui­si­tion

Last year
Pharma
Cell/Gene Tx

Ver­tex's $4.9B bet; Lay­offs at No­var­tis, Genen­tech, Sanofi; Star founders un­veil new star­tups; and more

Last year
Weekly

I-Mab CEO de­tails con­sid­er­a­tions be­hind Chi­na split, hints at po­ten­tial in-li­cens­ing

Last year
Deals
China

Boehringer In­gel­heim taps Sino Bio­pharm as Chi­nese part­ner for its emerg­ing can­cer pipeline

Last year
Deals
China

Medicxi backs Chi­nese biotech's next-gen KRAS G12C drug with $40M in­jec­tion

Last year
Financing
China

US-Chi­na ten­sions per­sist; Gen­mab's $1.8B ADC bet; New obe­si­ty start­up in town; ALS drug with­draw­al; and more

Last year
Weekly

For­eign in­vestors fled Chi­nese biotech af­ter the pan­dem­ic. They still haven’t come back

Last year
Financing
China

Gen­mab fu­els AD­C­s' hot streak with $1.8B buy­out of Pro­found­Bio

Last year
Deals

Three more I-Mab ex­ecs ex­it af­ter US/Chi­na op­er­a­tions split

Last year
People
China

Roivant an­nounces study win in eye dis­ease for Pfiz­er as­set, plans $1.5B share buy­back

Last year
Deals
R&D

Omega cuts 35% of work­force; Rhythm, Cer­voMed, Sur­rozen raise new fund­ing

Last year
News Briefing

Disc Med­i­cine blames 'out­sized' place­bo re­sponse on mixed Phase 2 da­ta in rare blood dis­or­der

Last year
R&D

Bris­tol My­er­s' Zeposia ex­pan­sion plans hit by Phase 3 set­back in Crohn's dis­ease

Last year
R&D
Pharma

Atai Life Sci­ences spot­lights ear­ly de­pres­sion da­ta for psy­che­del­ic ahead of big read­out

Last year
R&D

Up­dat­ed: FDA re­jects Re­gen­eron's bis­pe­cif­ic for lym­phoma over con­fir­ma­to­ry tri­al sta­tus

Last year
FDA+

Es­pe­ri­on eyes new com­mer­cial push for cho­les­terol-low­er­ing drugs af­ter big FDA la­bel ex­pan­sion

Last year
Pharma
FDA+

Re­turn of the megarounds; Nvidia’s AI pitch to biotech; Bay­er’s shake­up reach­es the top; As­traZeneca buys in­to ...

Last year
Weekly

As­traZeneca views $2B+ Fu­sion buy­out as ‘start­ing point’ for bet­ter ra­dio­phar­ma­ceu­ti­cals, com­bos

Last year
Deals
Pharma

As­traZeneca snaps up ra­dio­phar­ma part­ner for $2B up­front

Last year
Deals

WuXi fall­out re­ver­ber­ates; Phar­ma's top R&D spenders; Lil­ly teams up with Ama­zon; His­toric NASH ap­proval; and more

Last year
Weekly

Af­ter years of de­lay, BeiGene fi­nal­ly lands FDA ap­proval for its PD-1 drug

Last year
China
Pharma

Spruce Bio­sciences’ stock plum­mets in wake of PhI­Ib flop, biotech to cut staff

Last year
People
R&D

Star­tups raised mil­lions to in-li­cense drugs to Chi­na. Then the mod­el fell apart

Last year
Deals
China

Amy­lyx’s ALS dis­ap­point­ment; Lil­ly's Alzheimer's de­lay; Bay­er stays put; No­vo Nordisk's GLP-1 streak; and more

Last year
Weekly
First page Previous page 1234567 Next page Last page
A service from the Financial Times